In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a hiv integrase inhibitor

Drug Metabolism and Disposition

Volumn 41, Issue 2, 2013, Pages 353-361

  Reese, Melinda J ^a   Savina, Paul M ^a   Generaux, Grant T ^a   Tracey, Helen ^b   Humphreys, Joan E ^a   Kanaoka, Eri ^c   Webster, Lindsey O ^a   Harmon, Kelly A ^a   Clarke, James D ^b   Polli, Joseph W ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; ATORVASTATIN; BREAST CANCER RESISTANCE PROTEIN; CIMETIDINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIGOXIN; DOLUTEGRAVIR; ELACRIDAR; ESTRADIOL; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; INTEGRASE INHIBITOR; METFORMIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; NIFEDIPINE; ORGANIC ANION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 1; PHENACETIN; RITONAVIR; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INTESTINE ABSORPTION; LIVER CELL; MALE; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CHO CELLS; CRICETINAE; CRICETULUS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG INTERACTIONS; ENZYME INDUCTION; FEMALE; GLUCURONOSYLTRANSFERASE; HEPATOCYTES; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE INHIBITORS; HUMANS; ISOENZYMES; MADIN DARBY CANINE KIDNEY CELLS; MALE; MEMBRANE TRANSPORT PROTEINS; MICROSOMES, LIVER; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; TRANSFECTION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84872696364     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048918     Document Type: Article

References (50)

1. Benet LZ, Amidon GL, Barends DM, Lennernäs H, Polli JE, Shah VP, Stavchansky SA, and Yu LX (2008) The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res 25:483-488.
2. Benet LZ, Broccatelli F, and Oprea TI (2011) BDDCS applied to over 900 drugs. AAPS J 13: 519-547.
3. Bowen WP, Carey JE, Miah A, McMurray HF, Munday PW, James RS, Coleman RA, and Brown AM (2000) Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 28:781-788. (Pubitemid 30470828)
4. Busti AJ, Hall RG, and Margolis DM (2004) Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 24:1732-1747. (Pubitemid 39578961)
5. Chen Y, Tang Y, Guo C, Wang J, Boral D, and Nie D (2012) Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol 83:1112-1126.
6. Collier AC, Tingle MD, Keelan JA, Paxton JW, and Mitchell MD (2000) A highly sensitive fluorescent microplate method for the determination of UDP-glucuronosyl transferase activity in tissues and placental cell lines. Drug Metab Dispos 28:1184-1186.
7. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, and Unadkat JD (2007) Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 35:1853-1859. (Pubitemid 47481578)
8. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, and Hardcastle JD (1988) Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 29:1035-1041.
9. Giacomini KM, Huang SM, and Tweedie DJ, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
10. Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, and Backman JT (2006) Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 98:79-85.
11. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, and Desai PB (2004) Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 44:1273-1281. (Pubitemid 39391486)
12. Hesselink DA, van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, and van Gelder T (2005) Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistanceassociated protein 2. Am J Transplant 5:987-994. (Pubitemid 40571246)
13. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, and Karlsson J (2007) Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 35:1333-1340. (Pubitemid 47121774)
14. Hinton LK, Galetin A, and Houston JB (2008) Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharm Res 25:1063-1074. (Pubitemid 351521103)
15. Hull MW and Montaner JS (2011) Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med 43:375-388.
16. Imamura Y, Murayama N, Okudaira N, Kurihara A, Okazaki O, Izumi T, Inoue K, Yuasa H, Kusuhara H, and Sugiyama Y (2011) Prediction of fluoroquinolone- induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther 89:81-88.
17. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, and Sugiyama Y (1998) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38:461-499. (Pubitemid 28231503)
18. Iwamoto M, Wenning LA, and Petry AS, et al. (2008) Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 52:4338-4343.
19. Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, Azrolan N, Iwamoto M, Wagner JA, and Wenning LA (2007) Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 35:1657-1663. (Pubitemid 47296061)
20. Kivistö KT, Niemi M, and Fromm MF (2004) Functional interaction of intestinal CYP3A4 and Pglycoprotein. Fundam Clin Pharmacol 18:621-626. (Pubitemid 39564261)
21. Koteff J, Borland J, Chen S, Song I, Peppercorn A, Koshiba T, Cannon C, Muster H, and Piscitelli SC (2011) An open label, placebo-controlled study to evaluate the effect of dolutegravir (DTG, S/GSK1349572) on iohexol and para-aminohippurate clearance in healthy subjects. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2011 Sept 17-20; Chicago, IL. pp A1-A1724, GlaxoSmithKline, Inc., Research Triangle Park, NC.
22. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, Inoue K, Yuasa H, and Sugiyama Y (2011) Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 89:837-844.
23. Lepist EI, Murray BP, Tong L, Roy A, Bannister R, and Ray AS (2011) Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2011 Sept 17-20; Chicago, IL. pp A1-A1724, Gilead Sciences, Foster City, CA.
24. Lui CY, Amidon GL, Berardi RR, Fleisher D, Youngberg C, and Dressman JB (1986) Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci 75:271-274.
25. Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, and Piscitelli SC (2010) Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 54:254-258.
26. Mukwaya G, MacGregor T, Hoelscher D, Heming T, Legg D, Kavanaugh K, Johnson P, Sabo JP, and McCallister S (2005) Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother 49:4903-4910. (Pubitemid 41778900)
27. Palella FJ, Jr., Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, and Holmberg SD HIV Outpatient Study Investigators (2006) Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 43:27-34. (Pubitemid 44306484)
28. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, and Holmberg SD HIV Outpatient Study Investigators (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338:853-860. (Pubitemid 28135961)
29. Panel on Antiretroviral Guidelines for Adults and Adolescents (2012) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services, 1-161.
30. Polli JW, Humphreys JE, Harmon KA, Castellino S, O'Mara MJ, Olson KL, John-Williams LS, Koch KM, and Serabjit-Singh CJ (2008) The role of efflux and uptake transporters in [N-3-chloro-4-[(3- fluorobenzyl)oxy]phenyl-6-[5-([2- (methylsulfonyl)ethyl]aminomethyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 36:695-701. (Pubitemid 351468376)
31. Polli JW, Hussey E, Bush M, Generaux GT, Smith G, Collins D, McMullen S, Turner N, and Nunez DJ (2013) Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. Xenobiotica 43:498-508.
32. Polli JW,Wring SA,Humphreys JE,Huang L, Morgan JB,Webster LO, and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628. (Pubitemid 32979675)
33. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, and Polli JW (2006) In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34:786-792.
34. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, Wieman LM, Eisenberg EJ, and Rhodes GR (2006) Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 50:3297-3304. (Pubitemid 44527501)
35. Roukoz H and Saliba W (2007) Dofetilide: a new class III antiarrhythmic agent. Expert Rev Cardiovasc Ther 5:9-19. (Pubitemid 46157737)
36. Sarapa N, Wickremasingha P, Ge N, Weitzman R, Fuellhart M, Yen C, and Lloyd-Parks J (2007) Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iohexol. Antimicrob Agents Chemother 51:1912-1917. (Pubitemid 46903073)
37. Schützer KM, Svensson MK, Zetterstrand S, Eriksson UG, and Wåhlander K (2010) Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837. Eur J Clin Pharmacol 66:903-910.
38. Song I, Borland J, Chen S, Lou Y, Peppercorn A, Wajima T, Min S, and Piscitelli SC (2011a) Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br J Clin Pharmacol 72:103-108.
39. Song I, Borland J, Lou Y, Chen S, Patel P, Guta P, Wajima T, Peppercorn A, and Piscitelli SC (2011b) Effects of enzyme inducers, tipranavir and efavirenz, on the pharmacokinetics of the integrase inhibitor, dolutegravir (S/GSK1349572). 12th International Workshop on Clinical Pharmacology of HIV Therapy; 2011 Apr 13-15; Miami, FL. P 4, GlaxoSmithKline, Inc., Research Triangle Park, NC.
40. Song I, Borland J, Min S, Lou Y, Chen S, Patel P, Wajima T, and Piscitelli SC (2011c) Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother 55:3517-3521.
41. Song I, Min SS, Borland J, Lou Y, Chen S, Ishibashi T, Wajima T, and Piscitelli SC (2010) Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J Acquir Immune Defic Syndr 55:365-367.
42. Song I, Min SS, Borland J, Lou Y, Chen S, Patel P, Ishibashi T, and Piscitelli SC (2011d) The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J Clin Pharmacol 51:237-242.
43. Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C, and Biollaz J (2007) Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 64: 785-791. (Pubitemid 350222063)
44. van Lunzen J, Maggiolo F, and Arribas JR, et al. (2012) Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 12:111-118.
45. Yanakakis LJ and Bumpus NN (2012) Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos 40:803-814.
46. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ, Jr., Klein CE, Rublein JC, and Kashuba AD (2006) Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 42:52-60. (Pubitemid 43947946)
47. Zembruski NC, Büchel G, Jödicke L, Herzog M, Haefeli WE, and Weiss J (2011a) Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J Antimicrob Chemother 66:802-812.
48. Zembruski NC, Haefeli WE, and Weiss J (2011b) Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother 55:1282-1284.
49. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, and Humphreys WG (2005) In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 33:1729-1739. (Pubitemid 41539973)
50. Zhang L, Zhang YD, Strong JM, Reynolds KS, and Huang SM (2008) A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709-724.